|
|
|
|
|
Inactive Indication- |
Drug Highest PhasePhase 2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
A Prospective, Multi-center, Phase 1b/2a Study to Assess the Safety and Tolerability of Different Doses of AG019 Administered Alone or in Association With Teplizumab in Patients With Clinical Recent-onset Type 1 Diabetes Mellitus (T1D)
The purpose of this study is to assess the safety and tolerability of different doses of AG019 administered alone or in combination with teplizumab in participants with recent-onset type 1 diabetes (T1D).
100 Clinical Results associated with Precigen ActoBio T1D LLC
0 Patents (Medical) associated with Precigen ActoBio T1D LLC
100 Deals associated with Precigen ActoBio T1D LLC
100 Translational Medicine associated with Precigen ActoBio T1D LLC